Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
MELBOURNE, Australia and NEW YORK, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that it will present at the 34th Annual J. P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 13, 2016, at 3.30 p.m. PST/10.30am Thursday, January 14, 2016 (AEDT).
A live webcast of Mesoblast’s presentation can be accessed via either http://jpmorgan.metameetings.com/confbook/healthcare16/directlink?p=19955 or http://investorsmedia.mesoblast.com
The archived webcast will be available in the Events and Presentations section of the Company's website via www.mesoblast.com.
About Mesoblast
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) is a global leader in cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases where there are highly unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncology/hematology conditions.
For further information, please contact: Julie Meldrum Global Head of Corporate Communications Mesoblast Limited T: +61 3 9639 6036 E: [email protected]
